Over the past year, the S&P 500 benchmark has rewarded investors with an astonishing 40.6% rally. It's becoming harder and harder to find high-quality growth stocks that best its performance -- but they have not yet disappeared entirely.
Three high-flying stocks at a reasonable price are Bumble (BMBL -0.60%), Beyond Meat (BYND -4.29%), and Bausch Health Companies (BHC -3.20%). Let's look at why investors should consider the dating app company, the manufacturer making vegan protein products, and a multinational diversified pharma, respectively.
Bumble is a dating app with a unique feature -- letting women make the first move. This simple tweak has attracted an entire community of relationship seekers who may be disillusioned by conventional dating platforms like Tinder. Aside from running Bumble, the company also owns Badoo, a dating-focused social network with over 509 million users.
During the first quarter of 2021, Bumble's revenue increased by 51% year over year to $170.7 million. There are now a total of 2.8 million paid members on the Bumble and Badoo platforms, up from 2.15 million in the prior year's quarter. Another key metric, its average revenue per paying user, also increased by 13% year over year to $19.99 per quarter.
Moving forward, Bumble stock is a solid buy at 8 times revenue. Not only does it have solid sales growth ahead, but it is picking up steam in terms of generating operating income less non-cash expenses (EBITDA). For its excellent value proposition and rising member count, it is a solid tech stock to consider.
2. Beyond Meat
Beyond Meat is quickly revolutionizing the food industry with its plant-based meat substitutes. Using its proprietary science, the company is able to replicate the composition, core structure, and sensory experience of meats. Don't be dismayed if you are a meat lover; there are actually a lot of benefits to the company's approach.
For starters, people with mostly plant-based diets are 42% less likely to develop heart failure than those who focus on meat. In addition, a factory-based approach to "meat" production cuts out the use of agricultural land for livestock, meaning it is more sustainable for the environment.
The company's plant-based protein products are found in more than 118,000 retail stores and food service outlets worldwide. Last year, its net revenue amounted to $406.8 million, increasing 37% from 2019.
The stock may seem a little expensive at 16.4 times revenue. However, Beyond Meat has something other food companies don't -- its commitment to science. The company reinvests as much as 7.8% of its sales each year into research and development, which is 5.9 percentage points higher than the next leading competitor. Given its dedication to sustainability, it is an outstanding socially responsible stock to buy now.
3. Bausch Health Companies
Bausch Health Companies is a diversified pharma specializing in vision care, gastrointestinal treatments, and dermatology. For the next two years, the company forecasts it can grow its revenue and EBITDA by 4% and 5.5% per annum. It currently generates more than $8.4 billion in revenue and $3.425 billion in EBITDA.
The company's biggest hurdle is its gigantic debt balance. During a series of levered acquisitions, Bausch Health accumulated $23.985 billion worth of liabilities it's been struggling to pay off. It owes $1.46 billion each year in interest alone.
Fortunately, Bausch Health is exploring sales of its iconic contact lens business Bausch + Lomb to help balance the books. The company acquired the subsidiary in 2013 for $8.7 billion, and it has been a solid return on investment. Bloomberg estimates that Bausch + Lomb is now worth as much as $20 billion to $30 billion.
If the company completes a sale at that price, it would be enough money to let it start afresh. It is in desperate need of cash to reinvest in its pipeline in order to offset the loss of exclusivities on key products.
Right now, Bausch Health Companies is one of the cheapest pharma stocks out there at just 7.7 times price-to-earnings (P/E) and 1.3 times price-to-sales (P/S). The company is also backed by billionaire hedge fund managers such as Carl Icahn and John Paulson. Keep an eye out for its upcoming divestiture as a catalyst for growth.